Biomarker-Restricted Indication Urged For AstraZeneca’s Lynparza In First-Line Prostate Cancer

 
• By Sue Sutter
  
Big and small
AstraZeneca sought a broad indication for olaparib in mCRPC but appears likely to nab approval for a much smaller population. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers